Cambridge Healthtech Institute's Genome Tri-Conference

James W. Larkin jamesl at healthtech.com
Fri Oct 3 09:22:19 EST 1997


Cambridge Healthtech Institute's 
Genome Tri-Conference 
The Fairmont Hotel —San Francisco, California
February 9-15, 1998

The first two conferences highlight key technical progress and 
its application in the development of new therapeutic understanding 
and novel compounds. The third program showcases emerging genomics
companies and is designed to facilitate evaluation and networking.
Look closely at each meeting and decide to attend one, a pair, or 
all three. Our goal is to make the entire week work for you!

Special Multi-Conference Rates Available
Contact us directly, or visit the News/Features section of our 
website at http://www.healthtech.com/conferences/ for more information.

Fifth Annual
HUMAN GENOME PROJECT: Commercial Implications
February 9-11, 1998
Corporate Support Provided by: PE Applied Biosystems

As the Human Genome Project gears up into the sequencing 
phase, the expectations for translating such data into 
valuable information increase. While automated gel-based 
sequencing remains the workhorse of this effort, newer 
approaches have moved much closer to becoming practical. 
Much greater emphasis is also being placed on software 
for analyzing sequences and the creation of gene expression 
libraries and databases. Such databases, in combination 
with analysis of gene function, will play a key role in the 
identification of novel targets for diagnostic and therapeutic 
applications. The third day of this meeting will again feature 
case studies of genomic data-based drug development efforts. 
This meeting has become established as a key forum for academic 
and commercial researchers to discuss and find out about the 
latest technology and applied developments in the genomics 
field.

Scientific Advisors
        Dr. Roger Brent, Massachusetts General Hospital and 
                         Harvard Medical School
        Dr. Carol A. Dahl, National Cancer Institute
        Dr. Mark Schena, Stanford University Medical Center
        Dr. Robert L. Strausberg, National Cancer Institute

Overview
Keynote Presentations
A Toothpick-Wielding Microbial Geneticist Looks at the Future
        Dr. Ira Herskowitz, University of California, San Francisco
Perspective on Where Genomics Is Heading
        Dr. Randy Scott, Incyte Pharmaceuticals
The Hammer and the Handshake: Coordinate Approaches for Obtaining 
Meaningful Intellectual Property Protection and Operating in a 
Patent-Protected Environment in Genomics
        Dr. Kathleen Madden Williams, Banner & Witcoff Ltd.
Panel on Prospects for Genomic Investments
        Dr. Brian Atwood, Brentwood Venture Capital
        Dr. Jean-François Formela, Atlas Venture
        Dr. Hugh Reinhoff, Abingworth Venture Management, Inc.

Strategic Use of Genomic Information
Identifying Genes and Other Important Sequence Elements Using ESTs 
and Comparative Sequencing Efforts
        Dr. Richard Wilson, Washington University
Full-Length cDNA, an Entry to Function Determination
        Dr. C. Thomas Caskey, Merck Research Laboratories
Cancer Genome Anatomy Project
        Dr. Robert L. Strausberg
The Use of Information from Functional Genomics and Pharmacology 
in the Discovery of New Approaches to the Treatment of Human Disease
        Dr. Gordon Baxter, Pharmagene Laboratories Ltd.
Pharmacogenomics and Drug Prescription
        Dr. Marta Blumenfeld, Genset

Comprehensive Molecular Analysis Tools
Keynote Presentation
Assessing the Human Genome Project at the Halfway Point
        Dr. Francis S. Collins, National Human Genome Research 
                                Institute

Moving Beyond the Sequence: Protein-Based Tools for Assigning
Gene and Allele Function
        Dr. Roger Brent
ARAKIS, a Powerful Technology for Genome Sequencing and 
Clinical Diagnostic
        Dr. Hartmut Voss, Lion Bioscience AG
Automation for Cost Reduction in Large-Scale DNA Sequencing
        Dr. Andre Marziali, Stanford DNA Sequencing and Technology 
        Development Center
Integrating the Complementary Information from High-Throughput 
Sequencing and DNA Microarray Analysis
        Dr. David Barker, Molecular Dynamics
SELDI: Connecting Gene Expression Monitoring with Protein
Function and Drug Discovery
        Dr. William Hutchens, Ciphergen Biosystems

Parallel Analysis with Biological Chips
Accelerating Drug Discovery with Gene Expression Microarrays
        Dr. Dari Shalon, Synteni Inc.
Chip-Based Expression Analysis: Linking Sequence and Function
        Dr. Mark Schena
Genome Analysis Using SBH Tools
        Dr. Radoje Drmanac, Hyseq, Inc.
cDNA Arrays for the Masses
        Dr. Paul Siebert, Clontech Inc.
Integrated Microelectronic Systems for Genomic Research and
Diagnostic Applications
        Dr. Michael J. Heller, Nanogen, Inc.

Methods for Identification of Lead Genes
The First Gene Targets from a Novel Academic-Industry Liaison
        Dr. Richard E. Kouri, VIMRX Genomics, Inc.
Using Viral Signposts to Zoom In on Therapeutically Important Genes
        Dr. Subha Srinivasan, Immunex Corporation
Leveraging Bioinformatics and a Gene Expression Technology
Platform to Accelerate Lead Discovery
        Dr. Keith Elliston, Gene Logic, Inc.
Applications of Genomics in Target Identification and Lead
Development
        Dr. Douglas R. Smith, Genome Therapeutics Corporation
Aptameric Antagonists as Target Validation Tools
        Dr. Barry Polisky, NeXstar Pharmaceuticals

Genomic Drug Discovery
Novel Approaches to Drug Discovery Research
        Dr. Lee E. Babiss, Glaxo Wellcome Research and Development
New Approaches to Target Identification in Mouse and Man
        Dr. David Galas, Darwin Molecular Corporation
Pyrrole-Imidazole Polyamides as Specific Inhibitors of Gene
Transcription in Vitro and in Vivo
        Dr. Joel Gottesfeld, Scripps Research Institute
DiscoverEase™ Program for Identifying Secreted Proteins
        Dr. Sharan Pagano, Genetics Institute


Second Annual
GENE FUNCTIONAL ANALYSIS
February 12-13, 1998

As the complete genomes of the first model organisms become 
available, it is now possible to explore how well such data 
can be interpreted in terms of functional analysis. The sheer 
volume of genetic sequence is going to require a paradigm 
shift from laborious determination of function for one gene 
at a time to high-throughput approaches that can automatically 
assist in such efforts, via homolgy and cross-species 
comparisons. The use of libraries of mutants or knockouts 
also represents a key approach toward faster analysis.
Efforts to determine function of gene sequences and relate 
them to genetic pathways and roles in disease will be key for 
exploiting genetic information for medicinal purposes.

Scientific Advisors
        Dr. Doug Bassett, Fred Hutchinson Cancer Research Center
        Dr. Roger Brent, Massachusetts General Hospital and Harvard 
                         Medical School
        Dr. Edward M. Rubin, University of California, Berkeley

Keynote Presentation
        Dr. Patrick O. Brown, Stanford University School of Medicine

Functional Genomics
Model Organisms and Human Disease
        Dr. Doug Bassett
Genome Diversity and Functional Genomics
        Dr. Mark W. Bodmer, Hexagen
Gene Function Analysis by the Integration of Phenotypic and
Genotypic Databases
        Dr. Dirk Gewert, Gemini Biochemical Research
Identification of Critical Genes in Disease Pathways
        Dr. Lynne Zydowsky, Exelixis Pharmaceuticals
Large-Scale Functional Analysis of the S. Cerevisiae Genome
        Dr. Petra Ross-Macdonald, Yale University

Gene Expression
Using Protein Networks and Peptide Aptamers to Elucidate
Pathways, Genes, and Alleles
        Dr. Roger Brent
Functional Analysis in Silico
        Dr. Reinhard Schneider, Lion Bioscience AG
CodeSig™ Technology for Discovery of Variation in Gene Expression
        Dr. Gualberto Ruano, Genaissance Pharmaceuticals
Finding Genes Across Species
        Dr. Pavel Pevzner, University of Southern California
Linking Genome to Metabolome by High-Throughput Mass
Spectrometric Genetic Profiling: Novel Strategy to Unravel
Gene Function
        Dr. Adelbert A. Roscher, GeneValid GmbH
Genomic Analysis of C. Elegans
        Dr. Erik Sonnhammer, National Center for Biotechnology 
                             Information (invited)

Genome Manipulation
Radiation-Induced Deletions in Mice Using ES Cells
        Dr. John Schimenti, Jackson Laboratory
Exploiting the Mouse to Sift Sequence for Function
        Dr. Edward M. Rubin
OmniBank: An Engine of Drug Discovery
        Dr. Arthur T. Sands, Lexicon Genetics
Streamlined Approaches to Targeted Loss- and Gain-of-Function
Mouse Genetics
        Dr. George Gaitanaris, National Cancer Institute
Chromophore-Assisted Laser Inactivation
        Dr. Daniel Jay, Harvard University




More information about the Bio-soft mailing list